Effects of Torcetrapib in Patients at High Risk for Coronary Events
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib. METHODS: We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk. The patients received either torcetrapib plus atorvastatin or atorvastatin alone. The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina. RESULTS: At 12 months in patients who received torcetrapib, there was an increase of 72.1% in high-density lipoprotein cholesterol and a decrease of 24.9% in low-density lipoprotein cholesterol, as compared with baseline (P<0.001 for both comparisons), in addition to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P<0.001 for all comparisons). There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P=0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P=0.006). Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose reduction in potassium or increase in bicarbonate was greater than the median change. CONCLUSIONS: Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism. Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition. (ClinicalTrials.gov number, NCT00134264 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, BIA 10-2474 (Section 7.3) and torcetrapib (Section 7.5) are off-target toxicities that surfaced only at clinical exposures.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor designed to raise HDL-cholesterol, produced favourable surrogate-biomarker changes in trials but increased all-cause mortality in the ILLUMINATE outcome study.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“The mortality signal traced not to CETP inhibition itself but to off-target hemodynamic effects, including aldosterone elevation, blood pressure increases, and electrolyte shifts independent of the lipid mechanism [25].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“three large RCTs of cholesterol ester transfer protein inhibitors (dalcetrapib, evacetrapib, and torcetrapib) did not improve CV outcomes despite substantial increases in plasma HDL-C levels”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [20]
In the citing paper
“Furthermore, phase 3 trials of cholesteryl ester transfer protein inhibitors have shown that reducing LDL-C does not necessarily prevent CVD.”
From Saturated Fat Restriction for Cardiovascular Disease Prevention: A Systematic Review and Meta-analysis of Randomized Controlled Trials (2025) · cites this paper as [8]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Self-citationEffect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., & Tuzcu, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070635 · Cited by 966
Self-citationCholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Barter, P. J., Brewer, H. B., Chapman, M. J., Hennekens, C. H., Rader, D. J., & Tall, A. R. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054658.91146.64 · Cited by 870
Self-citationEffects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
Kastelein, J. J. P., van Leuven, S. I., Burgess, L., Evans, G. W., Kuivenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071359 · Cited by 658
Self-citationHDL as a target in the treatment of atherosclerotic cardiovascular disease
Linsel-Nitschke, P., & Tall, A. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1658 · Cited by 486
Self-citationHigh-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Bots, M. L., Visseren, F. L., Evans, G. W., Riley, W. A., Revkin, J. H., Tegeler, C. H., Shear, C. L., Duggan, W. T., Vicari, R. M., Grobbee, D. E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61088-5 · Cited by 461
Self-citation
Cited by
Items 101–200 of 1,017
Westerterp, M., Murphy, A. J., Wang, M., Pagler, T. A., Vengrenyuk, Y., Kappus, M. S., Gorman, D. J., Nagareddy, P. R., Zhu, X., Abramowicz, S., et al. (2013) · Circulation Research · doi:10.1161/circresaha.113.301086 · Cited by 299
“Although several different approaches to raising HDL are being actively pursued in clinical trials, recent failures in this arena have highlighted the need for a deeper understanding of the relationship between HDL and atheroprotection.(2,3) Infusion or increased production of HDL consistently leads to reduced atheros…”
MethodSelf-citationSpeer, T., Rohrer, L., Blyszczuk, P., Shroff, R., Kuschnerus, K., Kränkel, N., Kania, G., Zewinger, S., Akhmedov, A., Shi, Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.02.009 · Cited by 310
“…with a reduced risk for cardiovascular events (Miller et al., 1977), recent interventional trials using different approaches to raise HDL cholesterol serum concentrations failed to demonstrate a beneficial effect on CV mortality (Barter et al., 2007; Boden et al., 2011; Schwartz et al., 2012).”
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Anti-inflammatory therapeutics for the treatment of atherosclerosis
Charo, I. F., & Taub, R. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3444 · Cited by 306
“One example is the rise in high density lipoprotein (HDL) cholesterol that was observed in response to torcetrapib in the ILLUMINATE tria”
BackgroundWadhera, R. K., Steen, D. L., Khan, I., Giugliano, R. P., & Foody, J. M. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.11.010 · Cited by 306
Trials and Tribulations of CETP Inhibitors
Tall, A. R., & Rader, D. J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311978 · Cited by 305
Self-citationFerence, B. A., Kastelein, J. J. P., Ginsberg, H. N., Chapman, M. J., Nicholls, S. J., Ray, K. K., Packard, C. J., Laufs, U., Brook, R. D., Oliver-Williams, C., et al. (2017) · JAMA · doi:10.1001/jama.2017.11467 · Cited by 304
Self-citationCardioprotective functions of HDLs
Rye, K.-A., & Barter, P. J. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r039297 · Cited by 299
Self-citationChapman, M. J., Le Goff, W., Guerin, M., & Kontush, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp399 · Cited by 298
Beyond Mortality: Future Clinical Research in Acute Lung Injury
Spragg, R. G., Bernard, G. R., Checkley, W., Curtis, J. R., Gajic, O., Guyatt, G., Hall, J., Israel, E., Jain, M., Needham, D. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0024ws · Cited by 297
Ali, K. M., Wonnerth, A., Huber, K., & Wojta, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02081.x · Cited by 292
“…I and II studies (Brousseau et al., 2004; Davidson et al., 2006), in the large-scale phase III study, ILLUMINATE, torcetrapib therapy led to an increase in all-cause mortality and cardiovascular events, although it was able to increase HDL-C by 72% and decrease LDL-C by 25% (Barter et al., 2007).”
BackgroundLüscher, T. F., Landmesser, U., von Eckardstein, A., & Fogelman, A. M. (2014) · Circulation Research · doi:10.1161/circresaha.114.300935 · Cited by 291
“This finding was particularly surprising because HDL-C increased by 80% and LDL-C decreased by 25% as compared with atorvastatin alone.(8) Interestingly, in the RADIANCE 2 (Rating Atherosclerotic Disease Change by Imaging with a New Cholesteryl-EsterTransfer Protein Inhibitor) trial,(94) which used B-mode carotid ultr…”
Forrest, M. J., Bloomfield, D., Briscoe, R. J., Brown, P. N., Cumiskey, A., Ehrhart, J., Hershey, J. C., Keller, W. J., Ma, X., McPherson, H. E., et al. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.229 · Cited by 292
“Unfortunately, the study was terminated prematurely because of an unexpected increase in cardiovascular events and death with the combination treatment versus atorvastatin alone (Barter et al., 2007).”
BackgroundResultInfluentialAssessment of atherosclerosis: the role of flow-mediated dilatation
Charakida, M., Masi, S., Luscher, T. F., Kastelein, J. J. P., & Deanfield, J. E. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq340 · Cited by 290
“A major recent disappointment has been the results of the ILLUMINATE trial, which demonstrated an increase in CV events following administration of torcetrapib, despite a substantial rise in HDL cholesterol.(83) This has been attributed to ‘off target’ toxicity and it is tempting to speculate that an adverse signal mi…”
ResultSelf-citationTargeting inflammation in metabolic syndrome
Welty, F. K., Alfaddagh, A., & Elajami, T. K. (2016) · Translational Research · doi:10.1016/j.trsl.2015.06.017 · Cited by 287
Bergheanu, S. C., Bodde, M. C., & Jukema, J. W. (2017) · Netherlands Heart Journal · doi:10.1007/s12471-017-0959-2 · Cited by 282
“Torcetrapib was discontinued following a higher mortality in the torcetrapib arm of the ILLUMINATE trial [27], the results of the dalcetrapib trial (Dal-OUTCOMES) showed no clinical impact in acute coronary patients and the ACCELERATE trial of evacetrapib in acute coronary patients on statins was terminated prematurel…”
ResultImaging of atherosclerosis: carotid intima-media thickness
O'Leary, D. H., & Bots, M. L. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq185 · Cited by 280
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
(2010) · National Academies Press eBooks · doi:10.17226/12869 · Cited by 276
Krishna, R., Anderson, M. S., Bergman, A. J., Jin, B., Fallon, M., Cote, J., Rosko, K., Chavez-Eng, C., Lutz, R., Bloomfield, D. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61813-3 · Cited by 277
HDL cholesterol: reappraisal of its clinical relevance
März, W., Kleber, M. E., Scharnagl, H., Speer, T., Zewinger, S., Ritsch, A., Parhofer, K. G., von Eckardstein, A., Landmesser, U., & Laufs, U. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-017-1106-1 · Cited by 275
LDL cholesterol: controversies and future therapeutic directions
Ridker, P. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61009-6 · Cited by 274
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Malyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 273
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., De Leon, J., Glass, A. D., & Reiss, A. B. (2021) · Metabolites · doi:10.3390/metabo11100690 · Cited by 270
Afzal, S., Brondum-Jacobsen, P., Bojesen, S. E., & Nordestgaard, B. G. (2014) · BMJ · doi:10.1136/bmj.g6330 · Cited by 270
Factores de riesgo cardiovascular. Perspectivas derivadas del Framingham Heart Study
O’Donnell, C. J., & Elosua, R. (2008) · Revista Española de Cardiología · doi:10.1157/13116658 · Cited by 266
Cardiovascular Risk Factors. Insights From Framingham Heart Study
O'Donnell, C. J., & Elosua, R. (2008) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(08)60118-8 · Cited by 265
Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260
“atorvastatin alone) in the Investigation of Lipid Level Management to Understand its Impact on Atherosclerotic Events (ILLUMINATE) trial.(213) This was despite substantial elevation in HDL cholesterol levels (by 72%).”
BackgroundCongenital generalized lipodystrophies—new insights into metabolic dysfunction
Patni, N., & Garg, A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.123 · Cited by 261
Martín-Peláez, S., Covas, M. I., Fitó, M., Kušar, A., & Pravst, I. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200421 · Cited by 256
de Groot, E., van Leuven, S. I., Duivenvoorden, R., Meuwese, M. C., Akdim, F., Bots, M. L., & Kastelein, J. J. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1163 · Cited by 260
Self-citationKones, R. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 259
Diagnosis and treatment of familial hypercholesterolaemia
Hovingh, G. K., Davidson, M. H., Kastelein, J. J. P., & O'Connor, A. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht015 · Cited by 256
“A Phase III clinical trial with patients at high cardiovascular risk, receiving either torcetrapib in combination with atorvastatin or atorvastatin alone, was terminated early due to increased morbidity and mortality in patients receiving torcetrapib.(109) This study demonstrated potential off-target effects of torcet…”
BackgroundSelf-citationLipinski, M. J., Benedetto, U., Escarcega, R. O., Biondi-Zoccai, G., Lhermusier, T., Baker, N. C., Torguson, R., Brewer, H. B., & Waksman, R. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv563 · Cited by 256
ATP-Binding Cassette Transporters, Atherosclerosis, and Inflammation
Westerterp, M., Bochem, A. E., Yvan-Charvet, L., Murphy, A. J., Wang, N., & Tall, A. R. (2014) · Circulation Research · doi:10.1161/circresaha.114.300738 · Cited by 257
Self-citationHelgadottir, A., Gretarsdottir, S., Thorleifsson, G., Hjartarson, E., Sigurdsson, A., Magnusdottir, A., Jonasdottir, A., Kristjansson, H., Sulem, P., Oddsson, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3561 · Cited by 254
Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies
Jin, Q., & Ma, R. C. W. (2021) · Cells · doi:10.3390/cells10112832 · Cited by 252
Beyond High-Density Lipoprotein Cholesterol Levels
deGoma, E. M., deGoma, R. L., & Rader, D. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.016 · Cited by 253
Ridker, P. M., Genest, J., Boekholdt, S. M., Libby, P., Gotto, A. M., Nordestgaard, B. G., Mora, S., MacFadyen, J. G., Glynn, R. J., & Kastelein, J. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60713-1 · Cited by 256
Self-citationWebb, T. R., Erdmann, J., Stirrups, K. E., Stitziel, N. O., Masca, N. G. D., Jansen, H., Kanoni, S., Nelson, C. P., Ferrario, P. G., König, I. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.056 · Cited by 252
“However, several CETP inhibitors have recently failed to improve cardiovascular outcomes in large randomized clinical trials (28–30) and, in 1 case, caused harm (28), despite markedly increasing plasma HDL cholesterol.”
Tardif, J.-C., Ballantyne, C. M., Barter, P., Dasseux, J.-L., Fayad, Z. A., Guertin, M.-C., Kastelein, J. J. P., Keyserling, C., Klepp, H., Koenig, W., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu171 · Cited by 251
Self-citationVarbo, A., Benn, M., & Nordestgaard, B. G. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.008 · Cited by 251
“Finally, several drugs that inhibit CETP have been developed; however, results so far have either showed increased risk of cardiovascular disease of CETP inhibition on top of statins (Barter et al., 2007), or no effect on risk of cardiovascular disease (Schwartz et al.”
BackgroundLiu, C., Dhindsa, D., Almuwaqqat, Z., Ko, Y.-A., Mehta, A., Alkhoder, A. A., Alras, Z., Desai, S. R., Patel, K. J., Hooda, A., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0912 · Cited by 250
High-density lipoproteins, reverse cholesterol transport and atherogenesis
Pownall, H. J., Rosales, C., Gillard, B. K., & Gotto, A. M. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00538-z · Cited by 246
Endothelial dysfunction and coronary artery disease: assessment, prognosis, and treatment
Matsuzawa, Y., & Lerman, A. (2014) · Coronary Artery Disease · doi:10.1097/mca.0000000000000178 · Cited by 249
Xie, L., Li, J., Xie, L., & Bourne, P. E. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000387 · Cited by 247
“Also deducible was an explanation for the increased death from infection and cancer [21].”
BackgroundEffects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular Function
Lee, J. M. S., Robson, M. D., Yu, L.-M., Shirodaria, C. C., Cunnington, C., Kylintireas, I., Digby, J. E., Bannister, T., Handa, A., Wiesmann, F., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.036 · Cited by 246
Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes
Fleg, J. L., Mete, M., Howard, B. V., Umans, J. G., Roman, M. J., Ratner, R. E., Silverman, A., Galloway, J. M., Henderson, J. A., Weir, M. R., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.031 · Cited by 245
Nitrate and nitrite in the diet: How to assess their benefit and risk for human health
Habermeyer, M., Roth, A., Guth, S., Diel, P., Engel, K., Epe, B., Fürst, P., Heinz, V., Humpf, H., Joost, H., et al. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400286 · Cited by 243
“Of note, randomized clinical intervention trials have indicated a reduction in blood pressure of about 5 mm Hg to be significantly associated with decreased cardiovascular morbidity and mortality [156, 157], whereas a comparable increase was associated with the opposite effect [158].”
BackgroundPhentermine and topiramate for the management of obesity: a review
Uwaifo, G., Cosentino, & Conrad, A. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s31443 · Cited by 242
Bloomfield, D., Carlson, G. L., Sapre, A., Tribble, D., McKenney, J. M., Littlejohn, T. W., Sisk, C. M., Mitchel, Y., & Pasternak, R. C. (2009) · American Heart Journal · doi:10.1016/j.ahj.2008.09.022 · Cited by 243
“Moreover, patients treated with torcetrapib had reductions in K and increases in Na and bicarbonate, which are consistent with a pharmacodynamic effect of aldosterone excess.(7) In the present study, increasing doses of anacetrapib had no effect on aldosterone, Na, K, or bicarbonate compared with the control group.”
BackgroundResultInfluentialCoronary heart disease risk: Low-density lipoprotein and beyond
Shaya, G. E., Leucker, T. M., Jones, S. R., Martin, S. S., & Toth, P. P. (2022) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.04.002 · Cited by 236
HDL in Infectious Diseases and Sepsis
Pirillo, A., Catapano, A. L., & Norata, G. D. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-319-09665-0_15 · Cited by 237
“For instance, the increase in sepsis-related mortality of the ILLUMINATE trial observed in the torcetrapib (a cholesteryl ester transfer protein inhibitor, increasing HDL-C levels) arm (Barter et al. 2007) was unlikely due to a direct effect of torcetrapib on LBP or bactericidal/permeability increasing protein functio…”
BackgroundHovingh, G. K., Kastelein, J. J. P., van Deventer, S. J. H., Round, P., Ford, J., Saleheen, D., Rader, D. J., Brewer, H. B., & Barter, P. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60158-1 · Cited by 239
Self-citationYvan-Charvet, L., Kling, J., Pagler, T., Li, H., Hubbard, B., Fisher, T., Sparrow, C. P., Taggart, A. K., & Tall, A. R. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207142 · Cited by 240
Self-citationMora, S., Glynn, R. J., & Ridker, P. M. (2013) · Circulation · doi:10.1161/circulationaha.113.002671 · Cited by 237
Wilson, P. W. F., Polonsky, T. S., Miedema, M. D., Khera, A., Kosinski, A. S., & Kuvin, J. T. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.004 · Cited by 230
The Task Force on diabetes, P.-D. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114525548 · Cited by 236
Functional significance of cholesterol metabolism in cancer: from threat to treatment
Xiao, M., Xu, J., Wang, W., Zhang, B., Liu, J., Li, J., Xu, H., Zhao, Y., Yu, X., & Shi, S. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01079-w · Cited by 226
“Although CETP inhibitors, including torcetrapib, dalcetrapib, and evacetrapib, increase plasma HDL-C levels, these inhibitors are ineffective and cause adverse effects in patients 148 – 150 .”
High-Density Lipoprotein and Coronary Heart Disease
Natarajan, P., Ray, K. K., & Cannon, C. P. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.008 · Cited by 230
“As a result, there has been increasing interest in DL-C as a therapeutic target (13).”
BackgroundBalancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
Eichler, H.-G., Pignatti, F., Flamion, B., Leufkens, H., & Breckenridge, A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2664 · Cited by 229
“This occurred even though the treatment seemed to produce the anticipated favourable effects on lipid profile, highlighting the notion that even well-established surrogate end points might not predict the clinical outcome because the surrogate marker does not capture off-target effect”
BackgroundThe Relationship between Lung Inflammation and Cardiovascular Disease
Van Eeden, S., Leipsic, J., Paul Man, S. F., & Sin, D. D. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0455pp · Cited by 226
Pandor, A., Ara, R. M., Tumur, I., Wilkinson, A. J., Paisley, S., Duenas, A., Durrington, P. N., & Chilcott, J. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02062.x · Cited by 228
High-Density Lipoprotein Particle Size and Concentration and Coronary Risk
El Harchaoui, K., Arsenault, B. J., Franssen, R., Després, J.-P., Hovingh, G. K., Stroes, E. S. G., Otvos, J. D., Wareham, N. J., Kastelein, J. J. P., Khaw, K.-T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-2-200901200-00006 · Cited by 227
Self-citationKosmas, C. E., Martinez, I., Sourlas, A., Bouza, K. V., Campos, F. N., Torres, V., Montan, P. D., & Guzman, E. (2018) · Drugs in Context · doi:10.7573/dic.212525 · Cited by 225
Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products
Wang, D., Yang, Y., Lei, Y., Tzvetkov, N. T., Liu, X., Yeung, A. W. K., Xu, S., & Atanasov, A. G. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017178 · Cited by 226
“…progression of atherosclerosis (Tall, 1990; Nissen et al., 2003), a randomized, double-blind study involving 15,067 patients at high cardiovascular risk indicated that the CETP inhibitor torcetrapib raised the levels of HDL particles but failed to counteract atherosclerosis (Barter et al., 2007).”
BackgroundThe HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?
Vergeer, M., Holleboom, A. G., Kastelein, J. J. P., & Kuivenhoven, J. A. (2010) · Journal of Lipid Research · doi:10.1194/jlr.r001610 · Cited by 220
Self-citationBesler, C., Lüscher, T. F., & Landmesser, U. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200224 · Cited by 219
Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis
Yu, X.-H., Zhang, D.-W., Zheng, X.-L., & Tang, C.-K. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.12.002 · Cited by 218
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
“diovascular risk received the CETPi torcetrapib or placebo on top of atorvastatin.(39) Torcetrapib increased HDL-C by 72%, re-”
BackgroundKoren, M. J., Giugliano, R. P., Raal, F. J., Sullivan, D., Bolognese, M., Langslet, G., Civeira, F., Somaratne, R., Nelson, P., Liu, T., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.007012 · Cited by 218
The Emerging Paradigm of Network Medicine in the Study of Human Disease
Chan, S. Y., & Loscalzo, J. (2012) · Circulation Research · doi:10.1161/circresaha.111.258541 · Cited by 214
“102,103 Based on in silico predictions of protein-ligand binding, Xie et al identified a panel of off-targets for torcetrapib and other CETP inhibitors from the human structural genome and mapped those targets to a network of biological pathways curated from the literature.”
BackgroundLüscher, T. F., Taddei, S., Kaski, J.-C., Jukema, J. W., Kallend, D., Münzel, T., Kastelein, J. J. P., & Deanfield, J. E. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs019 · Cited by 217
“Low-density lipoprotein cholesterol did not change in contrast to torcetrapib and anacetrapib which lower LDL-C by 25 and 40%, respectively.(7,42) The increase in Lp-PLA2 mass of 17% seen with dalcetrapib is likely related to the increase in HDL-C itself.”
BackgroundResultSelf-citationHigh Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans
Bowe, B., Xie, Y., Xian, H., Balasubramanian, S., Zayed, M. A., & Al-Aly, Z. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00730116 · Cited by 213
Nicholls, S. J., Tuzcu, E. M., Brennan, D. M., Tardif, J.-C., & Nissen, S. E. (2008) · Circulation · doi:10.1161/circulationaha.108.790733 · Cited by 213
Self-citationXiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
Mendelian randomization studies in coronary artery disease
Jansen, H., Samani, N. J., & Schunkert, H. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu208 · Cited by 212
“did not confer the benefit as predicted from the epidemiological observations.(5) The large number of biomarkers, the uncertainty about their”
BackgroundMethodInfluentialGusarova, V., Alexa, C. A., Wang, Y., Rafique, A., Kim, J. H., Buckler, D., Mintah, I. J., Shihanian, L. M., Cohen, J. C., Hobbs, H. H., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054890 · Cited by 210
Hemingway, H., Asselbergs, F. W., Danesh, J., Dobson, R., Maniadakis, N., Maggioni, A., van Thiel, G. J. M., Cronin, M., Brobert, G., Vardas, P., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx487 · Cited by 209
“Costly, late drug failures occurring within phase III trials have been recently seen for CETP inhibitors which raise HDL-cholesterol (HDL-C), 73–75 ivab-radine which lowers the heart rate 76 and darapladib, a selective oral inhibitor of lipoprotein-associated phospholipase A 2 .”
BackgroundVarbo, A., Freiberg, J. J., & Nordestgaard, B. G. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.234146 · Cited by 209
Ferri, N., Siegl, P., Corsini, A., Herrmann, J., Lerman, A., & Benghozi, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.03.005 · Cited by 205
Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?
Otocka-Kmiecik, A., Mikhailidis, D. P., Nicholls, S. J., Davidson, M., Rysz, J., & Banach, M. (2012) · Progress in Lipid Research · doi:10.1016/j.plipres.2012.03.003 · Cited by 206
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome
Murphy, S. A., Cannon, C. P., Blazing, M. A., Giugliano, R. P., White, J. A., Lokhnygina, Y., Reist, C., Im, K., Bohula, E. A., Isaza, D., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.077 · Cited by 205
“(17,18), torcetrapib (19), and dalcetrapib (20).”
Self-citationChang, R. L., Xie, L., Xie, L., Bourne, P. E., & Palsson, B. Ø. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000938 · Cited by 204
“Torcetrapib was withdrawn from phase III clinical trials after a substantial investment of labor and capital due to its observed side effect of fatal hypertension in some patients [16].”
BackgroundRVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
McLure, K. G., Gesner, E. M., Tsujikawa, L., Kharenko, O. A., Attwell, S., Campeau, E., Wasiak, S., Stein, A., White, A., Fontano, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083190 · Cited by 198
Cardiovascular Drug Development
Fordyce, C. B., Roe, M. T., Ahmad, T., Libby, P., Borer, J. S., Hiatt, W. R., Bristow, M. R., Packer, M., Wasserman, S. M., Braunstein, N., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.016 · Cited by 202
Madsen, C. M., Varbo, A., Tybjærg-Hansen, A., Frikke-Schmidt, R., & Nordestgaard, B. G. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx665 · Cited by 201
“0 events).(25) This might reflect a qualitative difference in HDL raised in response to CETP inhibition different from that of ambient HDL measured in the general population.”
Barter, P. J., Rye, K.-A., Tardif, J.-C., Waters, D. D., Boekholdt, S. M., Breazna, A., & Kastelein, J. J. P. (2011) · Circulation · doi:10.1161/circulationaha.111.018259 · Cited by 198
Self-citationRecognition and Management of Dyslipidemia in Children and Adolescents
Kwiterovich, P. O. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1270 · Cited by 197
Ballantyne, C. M., Raichlen, J. S., Nicholls, S. J., Erbel, R., Tardif, J.-C., Brener, S. J., Cain, V. A., & Nissen, S. E. (2008) · Circulation · doi:10.1161/circulationaha.108.773747 · Cited by 201
Self-citationRidker, P. M., Paré, G., Parker, A. N., Zee, R. Y. L., Miletich, J. P., & Chasman, D. I. (2009) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.108.817304 · Cited by 200
Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis
Murphy, A. J., Bijl, N., Yvan-Charvet, L., Welch, C. B., Bhagwat, N., Reheman, A., Wang, Y., Shaw, J. A., Levine, R. L., Ni, H., et al. (2013) · Nature Medicine · doi:10.1038/nm.3150 · Cited by 196
Self-citationP. Mikhailidis, D., Elisaf, M., Rizzo, M., Berneis, K., Griffin, B., Zambon, A., Athyros, V., de Graaf, J., Marz, W., G. Parhofer, K., et al. (2011) · Current Vascular Pharmacology · doi:10.2174/157016111796642661 · Cited by 198
Coronary Atherosclerotic Plaque Regression
Dawson, L. P., Lum, M., Nerleker, N., Nicholls, S. J., & Layland, J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.10.035 · Cited by 196
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
Banach, M., Stulc, T., Dent, R., & Toth, P. P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.075 · Cited by 197
Boekholdt, S. M., Arsenault, B. J., Hovingh, G. K., Mora, S., Pedersen, T. R., LaRosa, J. C., Welch, K. M. A., Amarenco, P., DeMicco, D. A., Tonkin, A. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002670 · Cited by 196
“The trial evaluating the cholesteryl ester transfer protein inhibitors torcetrapib was stopped prematurely because of excess mortality in the torcetrapib arm, whereas the trial evaluating the cholesteryl ester transfer protein inhibitor dalcetrapib was terminated prematurely on the grounds of futility.(11,12) These da…”
ResultSelf-citationLoss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans
Edmondson, A. C., Brown, R. J., Kathiresan, S., Cupples, L. A., Demissie, S., Manning, A. K., Jensen, M. K., Rimm, E. B., Wang, J., Rodrigues, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37176 · Cited by 192
“The recent failure of torcetrapib (41), and the ongoing debate as to whether the increased mortality was an Table 6 Results of association analyses”
BackgroundEffects of Dietary Flavonoids on Reverse Cholesterol Transport, HDL Metabolism, and HDL function
Millar, C. L., Duclos, Q., & Blesso, C. N. (2017) · Advances in Nutrition · doi:10.3945/an.116.014050 · Cited by 192
“Furthermore, in light of the failures of HDL cholesterol–raising drugs (e.g., high-dose niacin and CETP inhibitors) to reduce CHD (17, 38), lifestyle changes or drug treatments that affect HDL functionality may prove to be more effective approaches.”
BackgroundInfluentialPalasubramaniam, J., Wang, X., & Peter, K. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312578 · Cited by 192
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 192
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192
“Among three CETP inhibitors developed originally (torcetrapib, dalcetrapib, and anacetrapib), torcetrapib was withdrawn following an excess of mortality in the torcetrapib arm of the Investigation of Lipid Levels Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.(153)”
Background
Metadata
- Authors
- Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., Shear, C. L., Revkin, J. H., Buhr, K. A., Fisher, M. R., Tall, A. R., & Brewer, B.
- Affiliations
- The Heart Research Institute (AU)
- St Bartholomew's Hospital (GB)
- Karolinska University Hospital (SE)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Hospital Universitario La Paz (ES)
- Columbia University (US)
- Montreal Heart Institute (CA)
- San Francisco General Hospital (US)
- Pfizer (United States) (US)
- University of Wisconsin–Madison (US)
- Columbia University Irving Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2109-2122
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2048760408
- Cited by
- 3,139
- References
- 15
- Citations by year
- 2026: 74 · 2025: 91 · 2024: 87 · 2023: 91 · 2022: 107 · 2021: 131 · 2020: 104 · 2019: 152 · 2018: 161 · 2017: 203 · 2016: 224 · 2015: 252 · 2014: 204 · 2013: 243 · 2012: 219
- FWCI
- 193.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- torcetrapib, cholesteryl ester transfer protein inhibition, cardiovascular events, high cardiovascular risk, atorvastatin, HDL cholesterol, LDL cholesterol, potassium, bicarbonate, aldosterone, mortality, off-target effects, drug safety
- MeSH terms
- Atorvastatin, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Mortality, Pyrroles, Quinolines, Cholesterol Ester Transfer Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.